Search clinical trials for: Fabrazyme (agalsidase beta)

Total 6074 results

Assistance Publique - Hôpitaux de Paris
Association Française contre les Myopathies (AFM), Paris

Completed

Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy (NEBIDYS)

Heart Failure | Duchenne Muscular Dystrophy | Cardiomyopathy

France
University Hospital, Basel, Switzerland

Completed

Thermogenesis in Hyperthyroidism and Effect of Anti-Adrenergic Therapy (HEAT)

Hyperthyroidism

Switzerland
University of California, San Diego
Forest Laboratories

Completed

Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension

Hypertension | Pre-hypertension

United States
Buddhist Tzu Chi General Hospital

Completed

Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Urinary Incontinence | Overactive Bladder Syndrome
Astellas Pharma Inc
Astellas Pharma Taiwan, Inc.

Completed

A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy Volunteers

Healthy Volunteer | Pharmacokinetics of YM178

Taiwan
Astellas Pharma Inc

Completed

A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects

Healthy Subjects | Plasma Concentration of Mirabegron

Japan
Hospital Sírio-Libanês

Recruiting

Determination of Autonomic Responses to the Exposure of Low Energy Electromagnetic Fields With Frequency Modulation in Patients With Advanced Hepatocellular Carcinoma and Healthy Individuals.

Hepatocellular Carcinoma

Brazil
Universitair Ziekenhuis Brussel

Unknown

IUI vs. IVF/ICSI in Women Aged 38-42 Years: a Prospective Randomized Controlled Trial.

Infertility

Belgium
Royal Brompton & Harefield NHS Foundation Trust
University of Oxford

Unknown

Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure (BB-META-HF)

Heart Failure

United Kingdom
University Hospital Schleswig-Holstein

Completed

Intravenous Beta-blockade for Improvement of Autonomic Activity

Hypertension | Tachycardia | Heart Rate Variability

Germany
Thammasat University

Unknown

Efficacy of Erythropoietin to Prevent Acute Kidney Injury in Chronic Kidney Disease Patients Undergoing Cardiac Surgery

Acute Renal Failure

Thailand
University of Texas at Austin

Recruiting

Beta-Hydroxybutyrate Feasibility Treating IBD (BHB)

Inflammatory Bowel Diseases | Crohn's Disease

United States
Banc de Sang i Teixits
Complexo Hospitalario Universitario de A Coruña; Institut Guttmann; Academic...

Completed

Cell Therapy for Chronic Traumatic Cervical Incomplete Spinal Cord Injury

Spinal Cord Injury Cervical

Spain
Prof. Franca Fagioli

Suspended

Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma

Osteosarcoma in Children

Italy
Sunstar Americas

Completed

GUIDOR® Growth Factor Enhanced Bone Graft Substitute for the Treatment of Periodontal Defects 6-months Post-Surgery

Periodontal Diseases | Alveolar Bone Loss

United States
Hoffmann-La Roche

Completed

An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Stage V Chronic Kidney Disease Participants on Hemodialysis

Anemia

South Africa
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia

Anemia

Belgium
Hoffmann-La Roche

Completed

A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

Anemia

Italy, Spain, United States, Germany
Hoffmann-La Roche

Completed

A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Anemia

United States
Hoffmann-La Roche

Completed

A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.

Anemia

India
Research and Education in Dentistry

Unknown

Vertical Augmentation With Osteon at Dental Implant Placement

Tooth Abnormalities | Tooth Injuries

United Kingdom
Jagiellonian University
University Hospital in Krakow

Not yet recruiting

Beta-blockade in Unruptured Intracranial Aneurysm (BBLURAN)

Intracranial Aneurysm

Poland
Meshalkin Research Institute of Pathology of Circulation

Recruiting

Esmolol for Myocardial Protection in Hypertrophic Obstructive Cardiomyopathy

Hypertrophic Obstructive Cardiomyopathy

Russian Federation
Philip Kern
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Mechanisms for Activation of Beige Adipose Tissue in Humans

PreDiabetes

United States
Astellas Pharma China, Inc.

Completed

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

Urge Incontinence | Overactive Bladder (OAB)

China
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Overactive Bladder | Pharmacokinetics of Mirabegron | Neurogenic Detrusor Overactivity

Belgium, Denmark, Norway, Poland, Serbia
Astellas Pharma Global Development, Inc.

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) (PILLAR)

Overactive Bladder (OAB)

United States, Canada
Philadelphia Urosurgical Associates
Astellas Pharma Global Development, Inc.

Terminated

A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis (MirabegronIC)

Cystitis, Interstitial

United States
Astellas Pharma Inc

Completed

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (ARIES)

Urinary Bladder, Overactive

United States, Canada
Astellas Pharma Inc

Completed

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (CAPRICORN)

Urinary Bladder, Overactive

United States, Hungary, Canada, Spain, Finland, Slovakia, Czechia, Sweden, Germany, Denmark, Norway
Massachusetts General Hospital
Forest Laboratories

Completed

Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease (NIRVANA)

Microvascular Angina

United States
Saint Francis Care
Biogen

Completed

Assessing Tolerability of Avonex Intramuscular Injections

Multiple Sclerosis

United States
Central Hospital, Nancy, France
Baxter Healthcare Corporation

Unknown

Esmolol Effects on Heart and Inflammation in Septic Shock (ESMOSEPSIS)

Septic Shock

France
Rempex Pharmaceuticals (a wholly owned subsidiary...

Completed

Safety, Tolerability, Pharmacokinetics of Intravenous RPX2014 and RPX7009 in Healthy Adult Subjects

Bacterial Infections | Healthy Volunteers

Australia
Astellas Pharma Inc

Completed

A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

Lower Urinary Tract Symptoms | Bladder Outlet Obstruction

United States, Canada
Astellas Pharma Inc

Completed

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

Renal Impairment

United States
Giulio Stefanini
Agenzia Italiana del Farmaco

Active, not recruiting

Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines (CONTROL)

Lymphoma, Large B-Cell, Diffuse | Breast Cancer | Chemotherapy Effect | Cardiotoxicity | Left Ventricular Dysfunction

Italy
Forest Laboratories

Completed

Nebivolol in Patients With Systolic Stage 2 Hypertension (NEB-MD-20)

Hypertension

United States
Qassim University

Unknown

Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic

COVID-19
University of California, San Diego

Recruiting

ADRB3 Signaling Pathway in Human Adipose Tissue

Obesity, Prediabetes

United States
Weill Medical College of Cornell University
National Institute on Aging (NIA)

Recruiting

A Preliminary Study for INFORMED (PRE-INFORMED)

Heart Diseases | Heart Failure | Heart Failure, Diastolic | Heart Failure With Preserved Ejection Fraction | Cardiac Failure

United States
University of Hohenheim

Recruiting

Age Related Effects Consuming Phaeodactylum Tricornutum (MIA_E)

Aging | Well Aging

Germany
Ain Shams University

Recruiting

Evaluating the Outcome of Cardio Selective beta1- Blockers Use in Patients With Copd

Copd

Egypt
National Taiwan University Hospital

Completed

Predictors for Retreatement of OAB After DC Mirabegron

Recurrence of Overactive Bladder Syndrome

Taiwan
Astellas Pharma Inc

Completed

Long-Term Specified Drug Use-results Survey of Betanis Tablets

Overactive Bladder

Japan
Qilu Hospital of Shandong University

Enrolling by invitation

A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism

Liver Cirrhosis | Esophageal and Gastric Varices | Hypersplenism

China
Aaron Boster
Pfizer; EMD Serono

Completed

Combination Therapy Using Cellcept and Rebif in RRMS

Multiple Sclerosis

United States
Henry M. Jackson Foundation for the Advancement...
Johns Hopkins University

Recruiting

Virtual Reality to Enhance Upper Extremity Physical Therapy and Recovery

Injuries to the Hand and Wrist

United States
Zhongshan Ophthalmic Center, Sun Yat-sen University

Not yet recruiting

Multimodal Equipment for Teleophthalmology Assessment (META)

Eye Diseases
Genentech, Inc.

Completed

A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease

Alzheimer's Disease

Search clinical trials for: Fabrazyme (agalsidase beta)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations